Pharmacoeconomics in Practice: QALY, ICER, and Evidence-Based Decision-Making

Pharmacoeconomics in Practice: QALY, ICER, and Evidence-Based

Decision-Making

Objectives:

•  To define key pharmacoeconomic concepts, including Quality-Adjusted Life Year (QALY) and

Incremental Cost-Effectiveness Ratio (ICER) and to understand the role of pharmacoeconomics

in healthcare systems and policy.

Date: August 14, 2025

Venue: Online Zoom 

Time: 7:00 to  10:00 P.M

CME hours: 3

Speaker: Dr. Hana Abdullah Alabdulkarim

Dr.Hana Al-Abdulkarim is currently the Director of Drug Policy and Economic

Center DPEC in NGHA (Riyadh, KSA). She is also the President of the International

Society for Pharmacoeconomics &Outcomes Research (ISPOR)-Saudi Arabia. Prior

to this, she worked as Health economist specializing mainly in conducting

pharmacoeconomic evaluations of Oncology/Hematolgy medications as a

member in Corporate P&T committee and all P&T subcommittees.

She has Pharmacy degree from King Saud University in KSA (2008). In 2012, she

completed Post-Graduate Diploma in Business and Law from University of

Sheffield, UK. In 2014, she obtained her master’s degree on Health Economics and

Decision Modeling from the University of Sheffield in UK in addition to training in

Health Economics at the University of Manchester. In 2018, she joined the HealthEconomics and Outcomes Research Certificate program from The University of

Washington, USA.